SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Trial Profile

SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Acronyms SAVANT
  • Sponsors Almirall Hermal GmbH
  • Most Recent Events

    • 23 Jun 2017 Status changed from recruiting to completed.
    • 11 Mar 2017 This trial has been completed in Austria.
    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top